Researchers in the U.S. and abroad are reporting progress on eliminating Porcine Reproductive and Respiratory Syndrome (PRRS), an incurable pig disease that costs the American pork industry as much as $660 million per year. However, regulatory hurdles and consumer perceptions are slowing down the commercialization of a possible cure through gene editing.
To view this article, please login
. If you are not a current subscriber, you may sign up for a trial or view other subscription options here